LEAWOOD, Kan., July 18, 2017 /PRNewswire/ -- Aratana
Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company
focused on the licensing, development and commercialization of
innovative therapeutics for dogs and cats, will host a live
conference call on Friday, August 4,
2017 at 8:30 a.m. ET to
discuss financial results from the second quarter ended
June 30, 2017.
Interested participants and investors may access the audio
webcast or use the conference call dial-in:
1 (866) 364-3820 (U.S.)
1 (855) 669-9657 (Canada)
1 (412) 902-4210 (International)
A replay of the second quarter results teleconference will be
available the same day of the event by approximately 11 a.m. ET and an audio webcast will be
accessible for 90 days in the Aratana Investor Room. For a replay
of the call, use the below dial-in and conference ID 10110825:
1 (877) 344-7529 (U.S.)
1 (855) 669-9658 (Canada)
1 (412) 317-0088 (International)
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on licensing, developing and
commercializing innovative therapeutics for dogs and cats. Aratana
believes that it can leverage the investment in the human
biopharmaceutical industry to bring therapeutics to dogs and cats
in a capital and time efficient manner. The company's pipeline
includes therapeutic candidates for the potential treatment of
pain, inappetence, viral diseases, allergy, cancer and other
serious medical conditions. Aratana believes the development and
commercialization of these therapeutics will permit veterinarians
and pet owners to manage pets' medical needs safely and
effectively, resulting in longer and improved quality of life for
pets. For more information, please visit www.aratana.com.
Contacts
For investor inquiries:
Craig Tooman
ctooman@aratana.com
(913) 353-1026
For media inquiries:
Rachel
Reiff
rreiff@aratana.com
(913) 353-1050
View original content with
multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-report-second-quarter-2017-financial-results-300490028.html
SOURCE Aratana Therapeutics, Inc.